Brooks Laboratories Limited (IN:BROOKS)

:BROOKS

BROOKS

Brooks Laboratories Limited

RESEARCH TOOLSreports

Brooks Laboratories Limited (BROOKS) Price & Analysis

1 Followers

BROOKS Stock Chart & Stats

₹123.65

-₹3.80(-2.00%)

At close: Jan 09 4:00 PM EST

₹123.65

-₹3.80(-2.00%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹165.95

Previous CloseN/A

Volume3.81K

Average Volume (3M)2.20K

Market Cap

₹1.58B

Enterprise Value₹1.65B

Total Cash (Recent Filing)₹18.03M

Total Debt (Recent Filing)₹78.33M

Price to Earnings (P/E)10.7

Beta1.32

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.87

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio0.59

Price to Book (P/B)3.42

Price to Sales (P/S)4.06

P/FCF Ratio-3.45K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Improved LeverageA sustained reduction in total debt and an improved debt-to-equity ratio strengthen financial flexibility and lower interest burden. Over 2–6 months this reduces refinancing risk and gives management room to invest in operations or R&D despite ongoing losses, supporting a steadier recovery path.

Operating Margin RecoveryNotable improvement in EBIT and EBITDA margins in 2025 indicates the company has started to control operating costs or improve mix. If sustained, higher operating margins provide a structural route to profitability and better cash generation, aiding long-term resilience even with current net losses.

Revenue Growth RecoveryA positive revenue growth rate and a 2025 recovery after earlier decline show demand resilience or successful commercial actions. Durable top-line recovery over several quarters supports scale economics, making margin improvements more sustainable and aiding longer-term cash-flow normalization.

Bears Say

Persistent Net LossesOngoing net losses erode equity and keep return measures negative, constraining retained-capital for reinvestment. Over the next few months this limits ability to self-fund growth, increases reliance on external financing, and raises the risk of dilution or asset sales if losses persist.

Negative Operating Cash FlowSustained negative operating cash flow indicates the business has not been generating internal cash to fund operations. Even with slight 2025 improvement, weak OCF and free cash flow create structural liquidity constraints, forcing recurring external funding and limiting long-term strategic flexibility.

Volatile Margins & RevenueMaterial volatility in revenue and gross margins signals inconsistent pricing, cost control, or product mix. Such instability increases forecasting risk and undermines confidence in sustained margin recovery, complicating efforts to convert improved EBIT/EBITDA into durable net-profitability.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

6M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹165.95 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹1.58B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Jun 01, 2026 which is in 57 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on Feb 06, 2026. The company reported ₹1.867 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.867.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of ₹1.867 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.747%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.